Here, we demonstrate that pharmacologic inhibition of C5a-C5aR1 signaling even after substantial plaque accumulation improved cognitive outcomes in the aggressive Arctic mouse model of AD, decreased transcription of disease-enhancing microglial genes while retaining protective gene expression and altered astrocyte polarization. Here, C5 is linked to Alzheimer disease.